Drug Development

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A biotech firm's novel marine compound, now patented, shows promise in modulating key cell pathways, offering a new strategy against intractable diseases.

Amid promising safety signals, Kazia Therapeutics expands its trial for paxalisib in TNBC, a strategic move offering new hope for a hard-to-treat cancer.

French biotech TreeFrog Therapeutics isn't just replacing cells; it's implanting pre-wired networks. Their novel 3D microtissue shows faster, more extensive brain repair.

Preliminary data shows IBI363 achieved an 86.4% response rate in advanced lung cancer patients who typically respond poorly to current immunotherapies.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

Gene Solutions' AI-driven multi-omics liquid biopsy platform makes waves at a major oncology conference, finding a ready market in Taiwan.

Pliant Therapeutics heads to ASCO with data on a novel drug designed to reawaken the immune system's attack on advanced, treatment-resistant tumors.

New data shows Moleculin Biotech's Annamycin avoids heart toxicity, a breakthrough that could transform treatment for leukemia and sarcoma patients.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

Teva's new once-monthly olanzapine injection could revolutionize schizophrenia care in Europe, offering hope for better treatment adherence and patient outcomes.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

Paris-based Ennov lands a major transatlantic investment to accelerate its AI platform, aiming to reshape global drug development and regulatory processes.

A novel drug is in clinical trials for depression, moving beyond neurotransmitters to target the brain's fundamental energy production and repair mechanisms.

A new clinical trial is testing a device that uses electricity to deliver chemo directly into tumors, a strategy that could revolutionize treatment.

IGI announces ISB 2301, a first-in-class antibody targeting three tumor antigens and activating both T and NK cells for a new assault on solid tumors.

A first-in-class drug for anxiety has entered patient trials, offering a novel approach that could reshape mental healthcare for millions.